📰 Psychedelics News

Curated updates on microdosing, research, policy, and community.

Filters

2025-11-30 Psychedelics Today

The Ram Dass Institute of Psychedelic Studies with The Dying Inaugural Event on Maui

The Ram Dass Institute of Psychedelic Studies with The Dying (RIPS)   brings together professionals from the conscious dying field and healthcare practitioners engaged in the therapeutic use of psychedelic m...

2025-11-30 The Psychedelic Blog (Substack)

Gratitude Revealed: McGregor’s Ibogaine Death & Huxley’s LSD Exit

This week’s Sunday Insider explores a fascinating symmetry between Conor McGregor & Aldous Huxley — two lives, two eras, one insight.

2025-11-29 Tripsitter (Substack)

Is Kanna Really “Nature’s MDMA”?

Spoiler: No — but what it does do is far more interesting.

2025-11-28 Psychedelics Today

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your Truth

In this episode, Michael Sapiro joins Kyle Buller to explore truth, healing, and psychedelic-assisted psychotherapy through the lens of his new book, Truth Medicine. A clinical psychologist, ordained Zen Buddhist monk...

2025-11-28 The Psychedelic Blog (Substack)

Why Psychedelic Gratitude Hits Different

Welcome to the Psychedelic Blog. I write about the impact of Psychedelics on Grieving, Relationships, Culture & Death.

2025-11-26 Psychedelics Today

What the Cancer Community Actually Needs from Psychedelic Care

By Anne Hamilton, JD, MA When people talk about psychedelic therapy, the focus usually stays on depression, trauma, or neuroplasticity. These conversations matter, but they rarely touch the existential fear that defin...

2025-11-26 Chacruna

From Siberia to Super Mario: Amanita muscaria Reconsidered

Join us for a timely and necessary conversation about Amanita muscaria's emergence as a global phenomenon, from traditional Siberian and Sámi ceremonial practices to rapidly expanding retreat centers, commercial marke...

Community
2025-11-26 Microdose (industry)

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals...

Research
2025-11-26 Psychedelics Today

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Holotropic Breathwork sits at the center of this wide ranging conversation between Psychedelics Today co-founders Joe Moore and Kyle Buller. Drawing from decades of personal practice and assorted types of breathwork f...

2025-11-26 DoubleBlind Magazine

Ego Death for the 1%?

Why billionaires are tripping for productivity, and what that means for the rest of us. [...] Read More... The post Ego Death for the 1%? appeared first on DoubleBlind Mag.

2025-11-25 Psychedelics Today

Navigators Film Club – Last Journey

Join us for a film screening with one of the subjects in this short film by Arthur Nazaryn. The film was created for Reason TV. Join Navigators today to attend! The screening will be followed by discussion with the fi...

2025-11-25 Psychedelics Today

Alexander Beiner – Psychedelics, Culture, and the Games We Play

Alexander Beiner joins Psychedelics Today to explore how psychedelics, culture, and power shape each other. A writer, facilitator, and co founder of the conference Breaking Convention and the media platform KAINOS, he...

2025-11-25 DoubleBlind Magazine

Santa | Dedicated email Nov 25

Santa | Dedicated email Nov 25 November 25, 2025 Hey friend, guess what? Santa is real. At DoubleBlind, we’ve seen our fair share of mushroom elixirs, tonics, and tinctures — but none like this. Santa is a first-of-it...

2025-11-25 PsyMed Ventures

Brain Shuttles: A New Path Into the Brain with James Gorman of the Wyss Institute

Business Trip by PsyMed Ventures, a podcast exploring the future of mental and brain health & the startups building it

2025-11-24 Microdosing Institute

Participant Experiences of Microdosed Lysergic Acid Diethylamide in a 6-Week Randomised Controlled Trial

This qualitative study (n=40) of healthy males following a double-blind placebo-controlled trial of LSD microdosing (10µg every third day for 6 weeks) found participants reported effects across emotions and mood, soci...

Microdosing Research